TISIDB

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	T-cell surface glycoprotein CD1e, membrane-associated: Golgi apparatus membrane; Single-pass type I membrane protein. Early endosome. Late endosome. Note=Predominantly localized in the trans-Golgi network in immature dendritic cells, and as a cleaved, soluble protein in the lysosome lumen of mature dendritic cells.; SUBCELLULAR LOCATION: T-cell surface glycoprotein CD1e, soluble: Lysosome lumen.
Domain	PF07654 Immunoglobulin C1-set domain PF16497 MHC-I family domain
Function	T-cell surface glycoprotein CD1e, soluble binds diacetylated lipids, including phosphatidyl inositides and diacylated sulfoglycolipids, and is required for the presentation of glycolipid antigens on the cell surface. The membrane-associated form is not active.

> Gene Ontology [ TOP ]
Biological Process	GO:0002250 adaptive immune response GO:0002475 antigen processing and presentation via MHC class Ib GO:0019882 antigen processing and presentation GO:0019884 antigen processing and presentation of exogenous antigen GO:0048003 antigen processing and presentation of lipid antigen via MHC class Ib GO:0048007 antigen processing and presentation, exogenous lipid antigen via MHC class Ib
Molecular Function	GO:0003823 antigen binding GO:0030881 beta-2-microglobulin binding GO:0030882 lipid antigen binding GO:0030883 endogenous lipid antigen binding GO:0030884 exogenous lipid antigen binding GO:0033218 amide binding GO:0042277 peptide binding GO:0071723 lipopeptide binding
Cellular Component	GO:0005769 early endosome GO:0005770 late endosome GO:0005775 vacuolar lumen GO:0043202 lysosomal lumen

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04530 Tight junction hsa04640 Hematopoietic cell lineage
Reactome	-

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CD1E and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CD1E in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CD1E in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.389	0.26
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.235	0.679
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.512	0.3
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.644	0.372
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.088	0.94
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.576	0.217
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.408	0.616
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.249	0.303
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.546	0.669
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.161	0.185
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.446	0.0239
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.729	0.00972

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CD1E in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	22.2	5.5	16.7	0.0222
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	22.2	6.8	15.4	0.0651
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	12.5	-12.5	0.52
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	10.5	0	10.5	0.135
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	0	13.6	0.279
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD1E. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD1E. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD1E. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD1E. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CD1E expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CD1E and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CD1E
Name	CD1e molecule
Aliases	CD1E antigen, e polypeptide; CD1e antigen; R2G1; hCD1e; leukocyte differentiation antigen; thymocyte antigen ......
Chromosomal Location	1q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CD1E collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CD1E